Using generic preference-based measures in mental health: Psychometric validity of the EQ-5D and SF-6D

British Journal of Psychiatry

Volumn 205, Issue 3, 2014, Pages 236-243

  Mulhern, Brendan ^a   Mukuria, Clara ^a   Barkham, Michael ^a   Knapp, Martin ^b,c   Byford, Sarah ^b   Soeteman, Djøra ^d   Brazier, John ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; CONVERGENT VALIDITY; DEPRESSION; ECONOMIC EVALUATION; EFFECT SIZE; EQ 5D; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MENTAL HEALTH; OUTCOME ASSESSMENT; PERSONALITY DISORDER; PSYCHOMETRY; SCHIZOPHRENIA; SF 6D; COST BENEFIT ANALYSIS; ECONOMICS; MENTAL HEALTH SERVICE; PERSONALITY DISORDERS; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; VALIDATION STUDY;

COST-BENEFIT ANALYSIS; HUMANS; MENTAL HEALTH; MENTAL HEALTH SERVICES; PERSONALITY DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84906985859     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.122283     Document Type: Article

References (41)

1. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, 2008.
2. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
3. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108.
4. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92.
5. Brazier JE, Roberts J. Estimating a preference-based index from the SF-12. Med Care 2004; 42: 851-9.
6. Brazier J. Measuring and valuing mental health for economic evaluation. J Health Serv Res Policy 2008; 13 (suppl 3): 70-5.
7. Brazier J. Is the EQ-5D fit for purpose in mental health? Br J Psychiatry 2010; 197: 348-9.
8. Lamers LM, Bouwmans CA, van Straten A, Donker MC, Hakkaart L. Comparison of EQ-5D and SF-6D utilities in mental health. Health Econ 2006; 15: 1229-36.
9. Peasgood T, Brazier J, Papaioannou D. A systematic review of the validity and responsiveness of EQ-5D and SF-6D for depression and anxiety. Health Economics and Decision Science (HEDS) paper 12/15 (available at http://eprints.whiterose.ac.uk/id/eprint/74659).
10. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-6D, in schizophrenia? A systematic review. Value Health 2011; 14: 907-20.
11. Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 2009; 195: 170-7.
12. Soeteman DI, Timman R, Trijsburg RW, Verheul R, Busschbach JVV. Assessment of the burden of disease among inpatients in specialized units that provide psychotherapy. Psychiatr Serv 2005; 56: 1153-5.
13. Soeteman DI, Verheul R, Delimon J, Meerman AMMA, van den Eijnden E, Rossum BV, et al. Cost-effectiveness of psychotherapy for cluster B personality disorders. Br J Psychiatry 2010; 196: 396-403.
14. Brazier JE, Connell J, Papaioannou D, Mukuria C, Mulhern B, O'Cathain A, et al. Validating generic preference-based measures of health in mental health populations and estimating mapping functions for widely used specific measures. Health Technol Assess 2014; in press.
15. Kendrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. Br J Psychiatry 2006; 188: 337-45.
16. Morrell CJ, Slade P, Warner R, Paley G, Dixon S, Walters SJ, et al. Clinical effectiveness of health visitor training in psychologically informed approaches for depression in postnatal women: pragmatic cluster randomised trial in primary care. BMJ 2009; 338: a3045.
17. Mukuria C, Brazier J, Barkham M, Connell J, Hardy G, Hutten R, et al. Cost-effectiveness of an Improving Access to Psychological Therapies service. Br J Psychiatry 2013; 202: 220-7.
18. Byford S, Knapp M, Greenshields J, Ukoumunne OC, Jones V, Thompson S, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a rational decision making approach. Psychol Med 2003; 33: 977-86.
19. Tyrer P, Tom B, Byford S, Schmidt U, Jones V, Davidson K, et al. Differential effects of manual assisted cognitive behavior therapy in the treatment of recurrent deliberate self-harm and personality disturbance: the POPMACT study. J Pers Disord 2004; 18: 102-16.
20. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry 2006; 189: 508-14.
21. Crawford MJ, Kilaspy H, Barnes TRE, Barrett B, Byford S, Clayton K. Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. BMJ 2012: 344: e846.
22. Soeteman D, Verheul R, Busschbach J. The burden of disease in personality disorders: diagnosis-specific quality of life. J Pers Disord 2008; 22: 259-68.
23. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd edn). Canadian Agency for Drugs and Technologies in Health, 2006.
24. Pharmaceutical Benefits Advisory Committee. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Commonwealth of Australia, 2008.
25. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1993; 67: 361-70.
26. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 2002; 52: 69-77.
27. Barkham M, Evans C, Margison F, McGrath G, Mellor-Clark J, Connell J, et al. The rationale for developing and implementing core batteries for routine use in service settings and psychotherapy outcome research. J Ment Health 1998; 7: 35-47.
28. Barkham M, Gilbert N, Connell J, Marshall C, Twigg E. Suitability and utility of the CORE-OM and CORE-A for assessing severity of presenting problems in psychological therapy services based in primary and secondary care settings. Br J Psychiatry 2005; 186: 239-46.
29. Evans C, Mellor-Clark J, Margison F, Barkham M, Audin K, Connell J, et al. CORE: Clinical Outcomes in Routine Evaluation. J Ment Health 2000; 9: 247-55.
30. Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, et al. Towards a standardised brief outcome measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry 2002; 180: 51-60.
31. Gilbody S, Richards D, Barkham M. Diagnosing depression in primary care using self-completed instruments: UK validations of PHQ-9 and CORE-OM. Br J Gen Pract 2007; 57: 650-2.
32. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality: SIDP-IV. American Psychiatric Press, 1995.
33. Ventura J, Lukoff D, Nuechterlein K, Liberman R, Green M, Shaner A. Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0) scales, anchor points and administration manual. Int J Methods Psychiatr Res 1993; 3: 227-43.
34. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
35. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 829-36.
36. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 2005; 187: 366-71.
37. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005; 79: 231-8.
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Erlbaum, 1988.
39. Connell J, Brazier J, O'Cathain A, Lloyd-Jones M, Paisley S. Quality of life of people with mental health problems: a synthesis of qualitative research. Health Qual Life Outcomes 2012; 10: 138.
40. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-36.
41. Mavranezouli I, Brazier J, Young T, Barkham M. Using Rasch analysis to form plausible health states amenable to valuation: the development of CORE-6D from a measure of common mental health problems. Qual Life Res 2011; 20: 321-33.